Barclays Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $0.46
Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) had its target price reduced by Barclays from $1.00 to $0.46 in a report published on Wednesday,Benzinga reports. Barclays currently has an underweight rating on the biotechnology company’s stock. A number of other analysts have also recently weighed in on ADAP. HC Wainwright decreased their price target on shares […]
Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) had its target price reduced by Barclays from $1.00 to $0.46 in a report published on Wednesday,Benzinga reports. Barclays currently has an underweight rating on the biotechnology company’s stock. A number of other analysts have also recently weighed in on ADAP. HC Wainwright decreased their price target on shares […]
